Quidel Corporation (QDEL) Earns Media Impact Score of 0.11
Media coverage about Quidel Corporation (NASDAQ:QDEL) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Quidel Corporation earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news stories about the company an impact score of 44.7833258118742 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Shares of Quidel Corporation (NASDAQ:QDEL) traded up 1.00% during mid-day trading on Wednesday, hitting $44.30. The company had a trading volume of 422,632 shares. The company’s market capitalization is $1.48 billion. Quidel Corporation has a 1-year low of $18.25 and a 1-year high of $45.55. The company has a 50-day moving average price of $39.04 and a 200-day moving average price of $30.21.
Quidel Corporation (NASDAQ:QDEL) last announced its quarterly earnings results on Wednesday, July 26th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.18). The company had revenue of $38.30 million for the quarter, compared to analyst estimates of $41.91 million. Quidel Corporation had a negative return on equity of 0.03% and a negative net margin of 0.03%. Quidel Corporation’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.11) earnings per share. On average, equities analysts anticipate that Quidel Corporation will post $0.29 EPS for the current year.
A number of analysts have commented on QDEL shares. TheStreet raised Quidel Corporation from a “c+” rating to a “b-” rating in a report on Thursday, July 6th. BidaskClub lowered Quidel Corporation from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 16th. Zacks Investment Research raised Quidel Corporation from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a report on Tuesday, July 18th. Canaccord Genuity raised Quidel Corporation from a “hold” rating to a “buy” rating in a report on Tuesday, July 18th. Finally, William Blair raised Quidel Corporation from a “market perform” rating to an “outperform” rating in a report on Tuesday, July 18th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Quidel Corporation currently has a consensus rating of “Buy” and an average price target of $44.00.
In other Quidel Corporation news, CEO Douglas C. Bryant sold 36,000 shares of the stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $33.83, for a total transaction of $1,217,880.00. Following the sale, the chief executive officer now directly owns 296,493 shares of the company’s stock, valued at approximately $10,030,358.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Douglas C. Bryant sold 12,000 shares of the stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $42.86, for a total value of $514,320.00. Following the sale, the chief executive officer now directly owns 296,493 shares in the company, valued at $12,707,689.98. The disclosure for this sale can be found here. Insiders have sold a total of 227,388 shares of company stock worth $8,274,312 over the last ninety days. 22.00% of the stock is owned by insiders.
About Quidel Corporation
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Ratings for Quidel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.